A药品名称: B药品名称: B与A对换
 药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
A药品
B药品
详细
Trilostane
Mepyramine
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Mepyramine.
Trilostane
Pasireotide
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Pasireotide.
Trilostane
Cariporide
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Cariporide.
Trilostane
Amisulpride
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Amisulpride.
Trilostane
Vernakalant
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Vernakalant.
Trilostane
Tandutinib
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Tandutinib.
Trilostane
Methsuximide
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Methsuximide.
Trilostane
Ezogabine
The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Indacaterol.
Trilostane
Farnesyl thiopyrophosphate
The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Indacaterol.
Trilostane
Fleroxacin
The risk or severity of QTc prolongation can be increased when Fleroxacin is combined with Indacaterol.
Trilostane
Vorinostat
The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Indacaterol.
Trilostane
Pheniramine
The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Indacaterol.
Trilostane
Ajmaline
The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Indacaterol.
Trilostane
Encainide
The risk or severity of QTc prolongation can be increased when Encainide is combined with Indacaterol.
Trilostane
Desflurane
The risk or severity of QTc prolongation can be increased when Desflurane is combined with Indacaterol.
Trilostane
Cyclizine
The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Indacaterol.
Trilostane
Bretylium
The risk or severity of QTc prolongation can be increased when Bretylium is combined with Indacaterol.
Trilostane
Landiolol
The therapeutic efficacy of Landiolol can be decreased when used in combination with Indacaterol.
Trilostane
Epanolol
The therapeutic efficacy of Indacaterol can be decreased when used in combination with Epanolol.
Trilostane
Esatenolol
The therapeutic efficacy of Indacaterol can be decreased when used in combination with Esatenolol.
免责声明:以上所展示的信息由企业自行提供,内容的真实性、准确性和合法性由发布企业负责,医药网对此不承担任何责任。
相关链接:医药研究数据| 医药资料| SDA药品评审中心| 中医网| 中药处方系统| 爱视立眼贴
专业提供药品信息、药品招商、药品代理、保健品招商、医药原料采购供应的中国药品信息网站平台
版权所有 © 2003-2028 盗冒必究  客服热线:0575-83552251 / 13754370441  QQ客服:药品信息客服
浙ICP备16010490号-2 增值电信业务经营许可证:浙B2-20220931 互联网药品信息服务资格证书编号:(浙)-经营性2023-0215 浙公网安备:330683240604819103159
 医药代理商群1:药药网药品采购交流医药代理商群2:药药网药品采购交流2医药代理商群3:药药网药品采购交流3